TGFβ1 treatment decreases pituitary tumor cell proliferation, and this inhibitory effect is amplified by MEK inhibitors, because TGFβ1/Smad pathway cross-talks with MEK/ERK1/2 pathway (23). This evidence concerns the gene TGFB1 and pituitary tumor.